Veterinary Medicines

Canigen CHPPi/LR, süstesuspensiooni pulber ja suspensioon koertele

Authorised
  • Canine distemper virus, strain Lederle, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Leptospira interrogans, Serogroup Canicola, Live
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
  • Rabies virus, strain VP12, Inactivated
Download as PDF

Product identification

Medicine name:
Canigen CHPPi/LR, süstesuspensiooni pulber ja suspensioon koertele
Active substance:
  • Canine distemper virus, strain Lederle, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Leptospira interrogans, Serogroup Canicola, Live
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
  • Rabies virus, strain VP12, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain Lederle, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine adenovirus 2, strain Manhattan, Live
    1000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine parvovirus, strain Cornell 780916, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine parainfluenza virus, strain Manhattan, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Leptospira interrogans, Serogroup Canicola, Live
    833.00
    million organisms
    /
    1.00
    dose
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
    833.00
    million organisms
    /
    1.00
    dose
  • Rabies virus, strain VP12, Inactivated
    1.00
    international unit(s)
    /
    1.00
    dose
Pharmaceutical form:
  • Powder and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AJ06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac S.A.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1361
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 16/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."